顺铂是一种抗肿瘤药物，用于治疗各种类型的癌症。其副作用之一是耳毒性，可能导致双侧不可逆的听力损失。儿科人群的耳毒性影响更大，因为它会影响语言习得。具有耳保护作用的药物的发现及其最佳给药方式已成为最大限度减少顺铂对听觉功能影响的重大挑战。目的是了解耳保护药物及其在预防性治疗顺铂引起的儿童耳毒性中的相关性。通过咨询数据库（包括 PubMed、Bireme、MedLine、LILACS、SciELO 和 ClinicalTrials.gov）进行综合审查。搜索策略是通过交叉描述符（DeCS 和 MeSH）和自由术语来执行的。选择以英语、西班牙语和葡萄牙语发表的研究，没有出版年份限制。随后，根据纳入和排除标准选择文章。 PubMed 共找到 736 篇文章，Bireme 中有 431 篇，MedLine 中有 425 篇，LILACS 中有 6 篇，SciELO 中有 0 篇，ClinicalTrials.gov 中有 4 篇。经过文献分析，选出12篇文章进行全面分析。有证据表明 8 种物质与顺铂一起使用时具有潜在的耳保护作用，这往往会最大限度地减少顺铂对听觉功能的影响。发现的物质有：氨磷汀、地塞米松、金雀异黄酮、银杏叶、番茄红素、N-乙酰半胱氨酸、虎杖甙和硫代硫酸钠。一般来说，这些药物在顺铂输注之前、期间或之后使用，具体取决于所选药物，通过静脉注射、口服或经鼓室注射，作为抗氧化疗法。这些物质的生化作用与其潜在的耳保护特性相关，包括氧自由基和亲电铂物质的灭活。使用这些物质可以减少耳毒性，减少顺铂引起的听力损失并提高生活舒适度，特别是对于儿童而言。

Cisplatin is an antineoplastic medicine used in the treatment for various types of cancer. Among its side effects is ototoxicity, which may result in a bilateral and irreversible hearing loss. The ototoxic effect in the pediatric population has a bigger impact as it compromises language acquisition. The discovery of drugs with otoprotective effects and the optimal way to administer them have become significant challenges in minimizing the impact of cisplatin regarding auditory function. The objective was to understand otoprotective drugs and their relevance in the preventive treatment to cisplatin-induced ototoxicity in childhood. An integrative review was conducted by consulting databases including PubMed, Bireme, MedLine, LILACS, SciELO, and ClinicalTrials.gov. The search strategy was performed by crossing descriptors (DeCS and MeSH) and free terms. Studies published in English, Spanish, and Portuguese were selected, with no publication year restrictions. Subsequently, articles were selected according to inclusion and exclusion criteria. A total of 736 articles were found in PubMed, 431 in Bireme, 425 in MedLine, 6 in LILACS, 0 in SciELO, and 4 in ClinicalTrials.gov. After document analysis, 12 articles were selected for full analysis. Evidence was found for 8 substances with potential otoprotective effects when used with cisplatin, which tend to minimize the impact of cisplatin regarding auditory function. The substances found were: Amifostine, Dexamethasone, Genistein, Ginkgo Biloba, Lycopene, N-acetylcysteine, Polydatin also Sodium Thiosulfate. In general, these drugs are applied before, during, or after cisplatin infusion, depending on the chosen drug, via intravenous, oral, or transtympanic injections, acting as antioxidant therapy. The biochemical effects of these substances are relevant to their potential otoprotective properties, including the inactivation of oxygen free radicals and electrophilic platinum species. The use of these substances can reduce ototoxicity, decreasing cisplatin-induced hearing loss and improving the confort of life, especially for children.